Increase in renal cytochrome P-450 and NADPH cytochrome c reductase activity following drug inhibition of hepatic monooxygenase activity.
D000638:Amiodarone / Q000494:pharmacology; D000818:Animals; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000032:analysis*; D007668:Kidney / Q000201:enzymology*; D008099:Liver / Q000187:drug effects* / Q000201:enzymology; D008297:Male; D009251:NADPH-Ferrihemoprotein Reductase / Q000032:analysis* / Q000037:antagonists & inhibitors; D051381:Rats; D011919:Rats, Inbred Strains
D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System; D009251:NADPH-Ferrihemoprotein Reductase; D000638:Amiodarone